Full enrollment of 360 patients anticipated in second half of 2019 Pivotal global study continues enrolling worldwide Potential for first new therapy in 15 years to address unmet medical need in MDS NEWTOWN, Pa., March 25, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc.
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday, March 26, 2019 NEWTOWN, Pa., March 19, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat
NEWTOWN, Pa., March 12, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will
NEWTOWN, Pa., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes
Invitation-only breakfast event sponsored by Onconova Therapeutics will also be webcast, beginning at 8:00 a.m. EST NEWTOWN, Pa., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel
NEWTOWN, Pa., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Steven M. Fruchtman, President & CEO, will present a company
Executive succession plan maintains momentum of recent significant advances Onconova well-positioned to deliver key milestones in 2019 for both intravenous and oral rigosertib, as well as other pipeline products NEWTOWN, Pa., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc.
SPA submitted to the FDA before year-end 2018, marking achievement of a key regulatory milestone Advancement of this Phase 3 program, in treatment-naïve higher risk first-line MDS patients, positions rigosertib in an expanded patient population with a more convenient mode of administration 2019
NEWTOWN, Pa., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Management will
Mr. Oler joins Onconova’s management team as Vice President, Corporate Development and General Counsel, after an impactful tenure at Spectrum Pharmaceuticals Hiring reflects Onconova’s commitment to execute business development transactions to support the global development of Rigosertib NEWTOWN,
